Sei Kwang Hahn obtained his B.S., M.S., and Ph.D. in the Department of Chemical and Biomolecular Engineering at Korea Advanced Institute of Science and Technology (KAIST). As the youngest Ph.D. at LG Chemical Group in 1996, he started his research on biodegradable polymer and then sustained release formulation of hGH, which was successfully commercialized in Korea under the trade name of Declage® in 2007. From 2001, he did his post-doctoral research with Prof. Allan Hoffman in the Department of Bioengineering at the University of Washington. After that, he worked for long acting formulation of various biopharmaceuticals at the Roche Group, Chugai Pharmaceutical Co. in Japan for more than three years. Since 2005, he has worked as a professor in the Department of Materials Science and Engineering at POSTECH, and an adjunct professor in the School of Interdisciplinary Bioscience and Bioengineering and in the Department of Creative IT Engineering at POSTECH. He was a consultant for Johnson & Johnson in New Jersey in 2008 and made a collaboration project contract with Hoffman-La Roche. In 2012, he joined in the Wellman Center for Photomedicine, Harvard Medical School and Massachusetts General Hospital for his sabbatical research supported by LG Yeonam Fellowship. Currently, he is a visiting professor at Stanford University starting from Feb 1, 2019. He was the Samsung Future Technology Committee Member for 2016-2018 and the Presidential Advisory Council on Science and Technology for 2017-2019. He is the founder and CEO of PHI BIOMED Co. He received the Controlled Release Society Award in 2018, the Minister of Health and Welfare Award in 2017, the Korean President Award in 2015 and Korean Minister of Education Award in 2013. He published more than 120 SCI journal papers including Nature Photonics, Nature Communications, Progress in Polymer Science, Advanced Materials, and ACS Nano, and filed more than 130 Korean and international patents. He is one of the editorial board members of ACS Biomaterials Science and Engineering, ACS Applied Bio Materials, Biomacromolecules, and an Associate Editor of Biomaterials Research.